SynthesisJournal of Crohn's & colitis2016
Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.
Synthesis in Journal of Crohn's & colitis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis.BMJ open gastroenterology · 2024Pooled it
- Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.World journal of gastroenterology · 2019Pooled it
- Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis.Medicine · 2018Pooled it
- Tacrolimus Bridging and Combination Therapy Following Infliximab and JAK Inhibitor Failure in Ulcerative Colitis: A Case Series.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Tacrolimus therapy for ulcerative colitis: a retrospective study of factors associated with inducing and maintaining remission.BMC gastroenterology · 2026Article
- Severe upper gastrointestinal involvement in ulcerative colitis successfully treated with sequential therapy using intravenous tacrolimus and upadacitinib: a case report.Frontiers in medicine · 2026Article
- A Clinical Prediction Model for Early Colectomy in Patients With Severe Ulcerative Colitis Treated With Tacrolimus.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Efficacy of High-Dose Methylprednisolone in Inducing Remission in Pediatric Acute Severe Ulcerative Colitis: Retrospective Study.Journal of clinical medicine · 2025Article
- Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching.Scientific reports · 2025Article
- Antibiotic combination therapy for the induction and maintenance of remission in patients with ulcerative colitis.Bioscience of microbiota, food and health · 2025Article
- Steroid-Refractory Acute Severe Ulcerative Colitis in Infliximab-Experienced Patients.GE Portuguese journal of gastroenterology · 2024Review
- Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research.Journal of clinical medicine · 2024Review
- Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.Intestinal research · 2024Article
- Choosing Therapies in Ulcerative Colitis.Journal of the Canadian Association of Gastroenterology · 2024Article
- Efficacy and safety of tacrolimus in older adults with ulcerative colitis: a retrospective study.BMC gastroenterology · 2024Article
- Acute severe ulcerative colitis: using JAK-STAT inhibitors for improved clinical outcomes.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
- Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis.Journal of clinical medicine · 2023Article
- Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study.Journal of gastroenterology · 2023Article
- Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy.Gut and liver · 2023Review
- Combination ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 25% of patients with ulcerative colitis [UC] experience a severe flare requiring steroid therapy to avoid colectomy. We performed a systematic review and meta-analysis to assess the efficacy of tacrolimus as a rescue therapy for active UC.
methodsElectronic databases were searched for relevant studies assessing the efficacy of tacrolimus for active UC. Outcomes included short- and long-term clinical response, colectomy free rates, and rate of adverse events in randomised controlled trials [RCTs] and observational studies.
resultsTwo RCTs comparing high trough concentration [10-15ng/ml] versus placebo [n = 103] and 23 observational studies [n = 831] were identified. Clinical response at 2 weeks was significantly higher with tacrolimus compared with placebo (risk ratio [RR] = 4.61, 95% confidence interval [CI] = 2.09-10.17, p = 0.15 x 10(-3)] among RCTs. Rates of clinical response at 1 and 3 months were 0.73 [95% CI = 0.64-0.81] and 0.76 [95% CI = 0.59-0.87], and colectomy-free rates remained high at 1, 3, 6, and 12 months [0.86, 0.84, 0.78, and 0.69, respectively] among observational studies. Among RCTs, adverse events were more frequent compared with placebo [RR = 2.01, 95% CI = 1.20-3.37, p = 0.83 x 10(-2)], but there was no difference in severe adverse events [RR = 3.15, 95% CI = 0.14-72.9, p = 0.47]. Severe adverse events were rare among observational studies [0.11, 95% CI = 0.06-0.20].
conclusionsIn the present meta-analysis, tacrolimus was associated with high clinical response and colectomy-free rates without increased risk of severe adverse events for active UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.